{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:36:17Z","timestamp":1790750177053,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>The purpose of this study was to investigate the value of the \u201ccerebellum\/ liver index for prognosis\u201d (CLIP) as a new prognostic marker in pretherapeutic <jats:sup>18<\/jats:sup>F-Fluorodeoxyglucose positron emission tomography (<jats:sup>18<\/jats:sup>F-FDG PET) in patients with follicular lymphoma treated by immunochemotherapy and rituximab maintenance, focusing on progression-free survival (PFS).<\/jats:p>\n            <jats:p>Clinicobiological and imaging data from patients with follicular lymphoma between March 2010 and September 2015 were retrospectively collected and 5-year PFS was determined. The conventional PET parameters (maximum standardized uptake value and total metabolic tumor volume) and the CLIP, corresponding to the ratio of the cerebellum maximum standardized uptake value over the liver SUVmean, were extracted from the pretherapeutic <jats:sup>18<\/jats:sup>F-FDG PET.<\/jats:p>\n            <jats:p>Forty-six patients were included. Eighteen patients (39%) progressed within the 5\u200ayears after treatment initiation. Five-year PFS was 78.6% when CLIP was &gt;4.0 and 42.0% when CLIP was &lt;4.0 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.04). CLIP was a significant predictor of PFS on univariate analysis (hazard ratio 3.1, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.049) and was near-significant on multivariate analysis (hazard ratio 2.8, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.07) with ECOG PS as a cofactor.<\/jats:p>\n            <jats:p>The CLIP derived from pretherapeutic <jats:sup>18<\/jats:sup>F-FDG PET seems to be an interesting predictive marker of PFS in follicular lymphoma treated by immunochemotherapy and rituximab maintenance. These results should be evaluated prospectively in a larger cohort.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028791","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T13:01:03Z","timestamp":1643979663000},"page":"e28791","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Cerebellum\/liver index in pretherapeutic 18F-FDG PET\/CT as a predictive marker of progression-free survival in follicular lymphoma treated by immunochemotherapy and rituximab maintenance"],"prefix":"10.1097","volume":"101","author":[{"given":"Fran\u00e7ois","family":"Godard","sequence":"first","affiliation":[{"name":"M\u00e9decine Nucl\u00e9aire, Institut Godinot, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Durot","sequence":"additional","affiliation":[{"name":"H\u00e9matologie Clinique, CHU de Reims, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Durot","sequence":"additional","affiliation":[{"name":"Radiologie, CHU de Reims, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hoeffel","sequence":"additional","affiliation":[{"name":"Radiologie, CHU de Reims, Reims, France"},{"name":"CReSTIC (Centre de Recherche en Sciences et Technologies de l\u2019Information et de la Communication), Universite\u0301 de Reims Champagne-Ardenne, Reims, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Delmer","sequence":"additional","affiliation":[{"name":"H\u00e9matologie Clinique, CHU de Reims, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8738-4841","authenticated-orcid":false,"given":"David","family":"Morland","sequence":"additional","affiliation":[{"name":"M\u00e9decine Nucl\u00e9aire, Institut Godinot, Reims, France"},{"name":"Laboratoire de Biophysique, UFR de m\u00e9decine, Universit\u00e9 de Reims Champagne-Ardenne, Reims, France"},{"name":"CReSTIC (Centre de Recherche en Sciences et Technologies de l\u2019Information et de la Communication), Universite\u0301 de Reims Champagne-Ardenne, Reims, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","article-title":"Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times","volume":"156","author":"Wahlin","year":"2012","journal-title":"Br J Haematol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"JCO"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s12185-012-1202-y","article-title":"Current and future management of follicular lymphoma","volume":"96","author":"Salles","year":"2012","journal-title":"Int J Hematol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","article-title":"Follicular lymphoma: evolving therapeutic strategies","volume":"127","author":"Kahl","year":"2016","journal-title":"Blood"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"288","DOI":"10.6004\/jnccn.2010.0021","article-title":"NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas","volume":"8","author":"Zelenetz","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1080\/10428194.2016.1253836","article-title":"Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients","volume":"58","author":"Rai","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2016.69.3747","article-title":"Metabolic tumor volume in lymphoma: hype or hope?","volume":"34","author":"Sch\u00f6der","year":"2016","journal-title":"J Clin Oncol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1200\/JCO.2016.70.4890","article-title":"Overestimated value of baseline total metabolic tumor volume at 18F-labeled fluorodeoxyglucose positron emission tomography in follicular lymphoma","volume":"35","author":"Adams","year":"2016","journal-title":"JCO"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12149-010-0415-5","article-title":"Decreased brain FDG uptake in patients with extensive non-Hodgkin's lymphoma lesions","volume":"24","author":"Hanaoka","year":"2010","journal-title":"Ann Nucl Med"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJM199311253292203","article-title":"Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma","volume":"329","author":"Solal-Celigny","year":"1993","journal-title":"N Engl J Med"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00259-018-4194-x","article-title":"Effect of blood glucose level on standardized uptake value (SUV) in 18F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements","volume":"46","author":"Eskian","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cpet.2013.10.006","article-title":"Brain: normal variations and benign findings in fluorodeoxyglucose-PET\/computed tomography imaging","volume":"9","author":"Berti","year":"2014","journal-title":"PET Clin"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","article-title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"key":"R27-20250504","article-title":"Imaging of early response to predict prognosis in the first-line management of follicular non-hodgkin lymphoma with iodine-131-rituximab radioimmunotherapy","volume":"7","author":"Kesavan","year":"2017","journal-title":"Diagnostics (Basel)"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1109\/TNS.2005.858222","article-title":"Reliability of uptake estimates in FDG PET as a function of acquisition and processing protocols using the CPET","volume":"52","author":"Feuardent","year":"2005","journal-title":"IEEE Transactions on Nuclear Science"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:06:36Z","timestamp":1746331596000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028791","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"assertion":[{"value":"2020-08-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}